Compare REX AI Equity Premium Income ETF (AIPI) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Amgen, Inc. — how do they compare? REX AI Equity Premium Income ETF trades at $37.4, while Amgen, Inc. trades at $415.45 (market cap $224.14B). The key difference: Amgen, Inc. pays a 2.43% dividend while REX AI Equity Premium Income ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | AMGN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $417.20 |
52-Week Low | $32.45 | $271.18 |
Market Cap | — | $224.14B |
Enterprise Value | — | $267.45B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI (REX AI Equity Premium Income ETF) trades at $37.41 with minimal daily movement (+0.19%). The ETF employs an option-writing strategy focused on AI-related equities, generating substantial weekly dividends averaging $0.24-0.26 per distribution. Technical indicators show mixed signals with bullish moving averages but overbought RSI levels. The fund's unique structure provides high income but faces sustainability concerns if AI market momentum falters.
AIPI offers exceptional yield potential through its weekly distribution model but carries structural risks including potential NAV erosion. The ETF's performance depends heavily on continued AI sector strength and effective options management. Investors should weigh the high income against the fund's capped upside and concentration in technology stocks during market volatility.
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
